2. Antibody-drug Conjugate/ADC Related GPCR/G Protein Apoptosis
  3. Antibody-Drug Conjugates (ADCs) Guanylate Cyclase Apoptosis
  4. Indusatumab vedotin

Indusatumab vedotin  (Synonyms: MLN0264; TAK-264)

Cat. No.: HY-P99662
Technical Support

Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis.

For research use only. We do not sell to patients.

Indusatumab vedotin Chemical Structure

Indusatumab vedotin Chemical Structure

CAS No. : 1514889-12-3

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Indusatumab vedotin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis[1].

IC50 & Target

Guanylate cyclase (GCC)[1]
In Vitro

Indusatumab vedotin (0.4-25 μg/mL; 72 h) causes antiproliferative effects in pancreatic cancer cell lines[1].
Indusatumab vedotin (12.5 μg/mL; 24 h) arrests cell cycle at G2/M in MIA PaCa-2 and PANC-1 cells, and causes the P-Hitone H3 production[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Indusatumab vedotin Related Antibodies

Western Blot Analysis[1]

Cell Line: MIA PaCa-2 and PANC-1 cells
Concentration: 12.5 μg/mL
Incubation Time: 24 hours
Result: Increased the protein level of P-Hitone H3, indicating tubulin polymerization.

Cell Cycle Analysis[1]

Cell Line: MIA PaCa-2 and PANC-1 cells
Concentration: 12.5 μg/mL
Incubation Time: 24 hours
Result: Decreased cell number in G1 phase and caused an induction of a G2/M arrest.

Western Blot Analysis[1]

Cell Line: GCC Knock cells and Pancreatic cancer cell lines: L3.6, MIA PaCa-2, Panc 03.27, Panc 05.04 and Panc 02.03
Concentration: 0.4 μg/mL, 0.8 μg/mL, 1.6 μg/mL, 3.1 μg/mL, 6.3 μg/mL, 12.5 μg/mL, and 25 μg/mL
Incubation Time: 72 hours
Result: Inhibited the cell viability of pancreatic cancer cells, but not GCC Knock cells.
In Vivo

Indusatumab vedotin (10 mg/kg; i.v.; once weekly for 17 days at least) dramatically decreased the growth rate of tumor[1].
Indusatumab vedotin shows strongly correlated biological activity with exposure in mice bearing one of six different xenograft models[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Pancreas Explant Xenograft Model in Mouse[1]
Dosage: 10 mg/kg
Administration: Intravenous injection in tail; once weekly for 17-50 days
Result: Inhibited the volume growth of 10 types tumors significantly.
CAS No.
SMILES

[Indusatumab vedotin]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Indusatumab vedotin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Indusatumab vedotin1514889-12-3MLN0264 TAK-264MLN 0264MLN-0264TAK264TAK 264TAK-264Antibody-Drug Conjugates (ADCs)Guanylate CyclaseApoptosisAntibody-Drug ConjugatesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Indusatumab vedotin
Cat. No.:
HY-P99662
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.